[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 1973

The Diabetic Retinopathy Study

Author Affiliations

Boston; San Juan, Puerto Rico; Madison; Washington, DC; Chicago; Minneapolis; Baltimore; Baltimore; Detroit; Seattle; Boston; Madison; Miami, Florida; Baltimore; Baltimore; Salt Lake City; Los Angeles; Philadelphia; Albany, New York; Iowa City

Arch Ophthalmol. 1973;90(5):347-348. doi:10.1001/archopht.1973.01000050349001

Diabetic retinopathy has become one of the four most common causes of blindness in the United States.1 Although photocoagulation has been employed in its treatment for more than ten years, its true value remains controversial. In spite of the need for objective, definitive evidence, an adequately controlled study of photocoagulation in the treatment of proliferative diabetic retinopathy has not been performed. This is not surprising, considering the complexity and expense of largescale clinical trials in chronic disease. However, as Inglefinger2 has aptly stated, "When serious diseases are treated by serious methods... then ethical as well as scientific considerations require that medicine depend on the most reliable and the best controlled data available—the kind of data that is sought by randomized clinical study."

In keeping with this admonition, a randomized clinical trial of photocoagulation in the treatment of proliferative diabetic retinopathy has been designed and launched. This study

First Page Preview View Large
First page PDF preview
First page PDF preview